Mishima, Japan

Sadami Kobari

This inventor holds 3 USPTO granted patents. Top assignee: Toyo Jozo Kabushiki Kaisha. Active years: 1976-1983.


% Patents Active = 100.0

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 86(Granted Patents)


Location History:

  • Mishima, JA (1976)
  • Mishima, JP (1983)

Company Filing History:


Years Active: 1976-1983

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Sadami Kobari

Introduction

Sadami Kobari is a notable inventor based in Mishima, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of peptides. With a total of 3 patents to his name, Kobari's work has implications for medical research and diagnostics.

Latest Patents

Kobari's latest patents include innovative peptides designed for specific applications. One of his notable inventions is a peptide for assaying human parathyroid hormone. Additionally, he has developed a peptide that is a C-terminal fragment of human chorionic gonadotropin. These advancements showcase his expertise in peptide synthesis and its applications in healthcare.

Career Highlights

Throughout his career, Kobari has been associated with Toyo Jozo Kabushiki Kaisha, where he has contributed to various research projects. His work has not only advanced scientific knowledge but has also paved the way for new diagnostic tools in medicine. His dedication to innovation is evident in the patents he has secured.

Collaborations

Kobari has collaborated with esteemed colleagues such as Shigeo Katsuragi and Kaoru Morita. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Sadami Kobari's contributions to the field of biotechnology through his innovative peptides highlight his role as a significant inventor. His work continues to influence medical research and diagnostics, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…